文献速递心脑血管急症

经导管主动脉瓣植入术患者延期经皮冠状动脉介入治疗(PRO-TAVI):一项研究者发起的多中心开放标签非劣效随机对照试验

Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial.
PubMed 文献 · Lancet · 2026-03-29
一句话结论在接受TAVI的冠心病患者中,延期PCI在1年全因死亡、心梗、卒中和大出血复合终点上非劣于TAVI前常规PCI(率差-1.7%,95%CI -9.5至6.2)。

PRO-TAVI试验在荷兰12家医院纳入466例接受TAVI的冠心病患者,1:1随机分为延期PCI组(233例)和TAVI前PCI组(233例)。主要终点为1年全因死亡、心肌梗死、卒中和大出血的复合终点,非劣效界值为11个百分点。延期组主要终点发生56例(24%),PCI组60例(26%),率差-1.7%(95%CI -9.5至6.2),HR 0.89(95%CI 0.62-1.28),非劣效P=0.0008,优效性P=0.68。作者认为,在选定患者中初始保守策略可能合适,但仍需个体化治疗决策。

要点

  • 在接受TAVI的冠心病患者中,延期PCI组1年复合终点24%(56/233)vs TAVI前PCI组26%(60/233),率差-1.7%(95%CI -9.5至6.2),达到预设11个百分点非劣效界值(非劣效P=0.0008)。
  • 延期PCI组 vs TAVI前PCI组的主要终点HR 0.89(95%CI 0.62-1.28),优效性检验P=0.68,两组无显著差异。
  • 作者认为,在选定患者中初始保守策略可能合适,但患者个体化治疗决策仍然至关重要。
  • 研究纳入荷兰12家医院的TAVI合并冠心病患者,中位年龄81岁(IQR 78-84),女性166/466(36%)。
  • 主要终点为非劣效设计,界值11个百分点,长期随访仍在进行中。

适用人群与场景

  • 接受TAVI的冠心病患者,来自荷兰12家医院,中位年龄81岁(IQR 78-84),女性166/466(36%)。
  • 随机分组按是否存在累及左前降支近段的冠心病进行分层。

研究设计与关键结果

  • 研究类型:研究者发起的多中心、开放标签、非劣效随机对照试验,在荷兰12家医院进行,1:1随机分配,随机区组大小为2和4,按是否累及左前降支近段分层。
  • 样本量:共纳入466例,延期PCI组233例,TAVI前PCI组233例;2021年10月7日至2024年11月19日入组。
  • 主要终点:1年全因死亡、心肌梗死、卒中和大出血的复合终点;延期组56/233(24%)vs PCI组60/233(26%),率差-1.7%(95%CI -9.5至6.2),HR 0.89(95%CI 0.62-1.28),非劣效P=0.0008,优效性P=0.68。
  • 非劣效界值:预设11个百分点,在意向治疗人群中检验。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT),非劣效设计,开放标签。
  • 试验注册:ClinicalTrials.gov NCT05078619,长期随访仍在进行中。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在接受TAVI的冠心病患者中,延期PCI在1年复合终点上非劣于TAVI前PCI,初始保守策略在选定患者中可能合适。
  • 作者指出,患者个体化治疗决策仍然至关重要。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Coronary artery disease is common in patients undergoing transcatheter aortic valve implantation (TAVI). We aimed to assess whether deferral of percutaneous coronary intervention (PCI) is non-inferior to routine PCI before TAVI in patients with coronary artery disease.

METHODS: In this investigator-initiated, open-label, randomised controlled trial, done at 12 hospitals in the Netherlands, TAVI patients with coronary artery disease were randomly assigned in a 1:1 ratio to deferral of PCI or PCI before TAVI. Randomisation was done by use of a web-based system with random block sizes of 2 and 4, and stratification by presence of coronary artery disease involving proximal left anterior descending artery. The primary endpoint was a composite of all-cause mortality, myocardial infarction, stroke, and major bleeding at 1 year. Non-inferiority testing was done in the intention-to-treat population against the prespecified margin of 11 percentage points. The study is registered with ClinicalTrials.gov (NCT05078619) and long-term follow-up is ongoing.

FINDINGS: Between Oct 7, 2021, and Nov 19, 2024, 466 patients were enrolled: 233 were assigned to deferral of PCI and 233 to PCI before TAVI. Median age was 81 years (IQR 78-84), and 166 (36%) of 466 patients were female. The primary endpoint occurred in 56 (24%) of 233 patients in the deferral group as compared with 60 (26%) of 233 patients in the PCI group (rate difference -1·7% [95% CI -9·5 to 6·2]; hazard ratio 0·89 [95% CI 0·62-1·28]; p=0·0008 for non-inferiority; p=0·68 for superiority).

INTERPRETATION: In patients with coronary artery disease undergoing TAVI, deferral of PCI was non-inferior to PCI before TAVI for the 1-year composite of all-cause mortality, myocardial infarction, stroke, and major bleeding. These findings suggest that an initial conservative strategy can be appropriate in selected patients, although patient-tailored treatment decisions remain essential.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Delewi R, Aarts HM, Broeze GM, et al. Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial. Lancet. 2026. PMID: 41921523. doi:10.1016/S0140-6736(26)00308-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。